132 related articles for article (PubMed ID: 22418874)
1. Willingness to pay in dermatology: assessment of the burden of skin diseases.
Seidler AM; Bayoumi AM; Goldstein MK; Cruz PD; Chen SC
J Invest Dermatol; 2012 Jul; 132(7):1785-90. PubMed ID: 22418874
[TBL] [Abstract][Full Text] [Related]
2. Preference-based measures in dermatology: an overview of utilities and willingness to pay.
Seidler AM; Kini SP; DeLong LK; Veledar E; Chen SC
Dermatol Clin; 2012 Apr; 30(2):223-9, xiii. PubMed ID: 22284136
[TBL] [Abstract][Full Text] [Related]
3. Comparing willingness-to-pay and time-trade-off as the measures of burden of psoriasis: A pooled analysis of community, hospital, and web-based samples in China.
Shen M; Xiao H; Zhu W; Lu Y; Jing D; Kuang Y; Li M; Guan X; Sheng P; Su J; Chen X; Xiao Y
J Dermatol; 2022 Nov; 49(11):1131-1138. PubMed ID: 35906766
[TBL] [Abstract][Full Text] [Related]
4. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?
Schiffner R; Schiffner-Rohe J; Gerstenhauer M; Hofstädter F; Landthaler M; Stolz W
Br J Dermatol; 2003 Jun; 148(6):1153-60. PubMed ID: 12828743
[TBL] [Abstract][Full Text] [Related]
5. A catalog of dermatology utilities: a measure of the burden of skin diseases.
Chen SC; Bayoumi AM; Soon SL; Aftergut K; Cruz P; Sexton SA; McCall CO; Goldstein MK
J Investig Dermatol Symp Proc; 2004 Mar; 9(2):160-8. PubMed ID: 15083784
[TBL] [Abstract][Full Text] [Related]
6. Willingness to pay and quality of life in patients with pruritic skin disorders.
Stefanidou M; Evangelou G; Kontodimopoulos N; Koumaki D; Krueger-Krasagakis SE; Yosipovitch G; Krasagakis K
Arch Dermatol Res; 2019 Apr; 311(3):221-230. PubMed ID: 30788568
[TBL] [Abstract][Full Text] [Related]
7. Willingness to Pay and Time Trade-off in Thai Patients with Port-Wine Stains.
Jantarakolica T; Wanitphakdeedecha R; Yan C; Yogya Y; Sirisuthivoranunt S; Wongdama S; Phumariyapong P; Sudhipongpracha T
Clinicoecon Outcomes Res; 2022; 14():635-642. PubMed ID: 36171909
[TBL] [Abstract][Full Text] [Related]
8. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
[TBL] [Abstract][Full Text] [Related]
9. Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in Thai population.
Leeyaphan C; Wanitphakdeedecha R; Manuskiatti W; Kulthanan K
BMC Dermatol; 2011 Dec; 11():16. PubMed ID: 22182399
[TBL] [Abstract][Full Text] [Related]
10. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study.
Hu SW; Holt EW; Husni ME; Qureshi AA
Semin Arthritis Rheum; 2010 Apr; 39(5):384-97. PubMed ID: 19095293
[TBL] [Abstract][Full Text] [Related]
11. Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis.
Cham PM; Chen SC; Grill JP; Jonk YC; Warshaw EM
Br J Dermatol; 2007 May; 156(5):922-8. PubMed ID: 17459013
[TBL] [Abstract][Full Text] [Related]
12. Willingness to pay for a cure of low-risk melanoma patients in Germany.
Augustin M; Blome C; Forschner A; Gutzmer R; Hauschild A; Heinzerling L; Livingstone E; Loquai C; Schadendorf D; Utikal J; Wagner T; Wilden S; Kähler KC
PLoS One; 2018; 13(5):e0197780. PubMed ID: 29795621
[TBL] [Abstract][Full Text] [Related]
13. Willingness-to-pay and Time Trade-off: The Burden of Disease in Patients with Benign Hyperpigmentation.
Maymone MBC; Rajanala S; Widjajahakim R; Secemsky E; Saade D; Vashi NA
J Clin Aesthet Dermatol; 2019 May; 12(5):46-48. PubMed ID: 31320977
[No Abstract] [Full Text] [Related]
14. Willingness to pay and quality of life in patients with rosacea.
Beikert FC; Langenbruch AK; Radtke MA; Augustin M
J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):734-8. PubMed ID: 22583164
[TBL] [Abstract][Full Text] [Related]
15. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
Olofsson S; Norrlid H; Persson U
J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
[TBL] [Abstract][Full Text] [Related]
16. Implementation of Instrument Based on Eight Health Related Quality of Life Domains for Measuring of Willingness to Pay for Psoriasis Treatment.
Dobrev HP; Atanasov NG; Dimitrova DD
Folia Med (Plovdiv); 2017 Sep; 59(3):326-335. PubMed ID: 28976906
[TBL] [Abstract][Full Text] [Related]
17. Psychological Burden and Willingness to Pay Among Korean Rosacea Patients and Their Association With Rosacea Phenotype and Severity: A Multi-Center Cross-Sectional Study.
Woo YR; Kim S; Cho SH; Kim HS
J Cutan Med Surg; 2023 Nov; 27(6):601-607. PubMed ID: 37587799
[TBL] [Abstract][Full Text] [Related]
18. Defining monetary values for quality of life improvements: an exploratory study.
Lachaine J; Laurier C; Contandriopoulos AP
Pharmacoeconomics; 2003; 21(12):865-74. PubMed ID: 12908842
[TBL] [Abstract][Full Text] [Related]
19. Assessing Medicare beneficiaries' willingness-to-pay for medication therapy management services.
Woelfel JA; Carr-Lopez SM; Delos Santos M; Bui A; Patel RA; Walberg MP; Galal SM
Consult Pharm; 2014 Feb; 29(2):104-9. PubMed ID: 24513420
[TBL] [Abstract][Full Text] [Related]
20. Willingness to pay: a valid and reliable measure of health state preference?
O'Brien B; Viramontes JL
Med Decis Making; 1994; 14(3):289-97. PubMed ID: 7934716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
